Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @BioPharmaDive
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BioPharmaDive
-
$REGN hopes to replicate its past success in quickly advancing a treatment for Ebola. But, as that experience showed, proving a new antiviral isn't easy.https://www.biopharmadive.com/news/regeneron-hhs-coronavirus-antibody-development/571651/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$GILD acknowledged the cell therapy developer is worth less than it once thought, cutting the accounting value for research assets it acquired by $800Mhttps://www.biopharmadive.com/news/gilead-yescarta-cell-therapy-writedown-deal-pressure/571762/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
With $200M more in bank,
$AIMT also in-licensed an experimental next-generation food allergy therapy from$XNCRhttps://www.biopharmadive.com/news/nestle-aimmune-200-million-investment-peanut-allergy-xencor/571763/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A yet-to-be-named new company will house
$MRK's women's health, biosimilar and legacy drugs, providing space and resources for the pharma's higher-growth businesses.https://www.biopharmadive.com/news/merck-joins-pharma-peers-spin-off-legacy-drugs/571766/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Anteros Pharmaceuticals is the first company made via a partnership between
$BMY and biotech accelerator BioMotiv. Its initial targets are liver and lung fibrosis, with one specific focus being IPF.https://www.biopharmadive.com/news/bristol-myers-biomotive-launch-anteros-biotech/571650/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$PFE,$GSK and$AGN were the most active, collectively raising list prices on some 450 drugs this Jan., according to one Wall Street analyst.https://www.biopharmadive.com/news/january-drug-price-increase-trump-state-union/571676/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
HHS and
$REGN previously worked together on an experimental Ebola treatment that proved effective in the 2018 outbreak of that disease.https://www.biopharmadive.com/news/regeneron-hhs-coronavirus-antibody-development/571651/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$AIMT's next challenge will be securing insurance coverage as people allergic to peanuts still have to avoid exposure to the food.https://www.biopharmadive.com/news/aimmune-fda-approval-palforzia-peanut-allergy/571524/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
With biologics driving growth,
$CTLT is looking to diversify with a $315M purchase that hands it a slate of production sites.https://www.biopharmadive.com/news/catalent-expecting-a-boon-in-cell-therapy-bids-for-masthercell/571593/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Research into preventive treatments will continue, however, as an NIH leader declared a vaccine "essential" to ending the widespread disease.https://www.biopharmadive.com/news/nih-stop-hiv-vaccine-study-uhambo/571594/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$GILD will work with Chinese authorities to test its drug remdesivir, while$GSK is providing its adjuvant platforms to groups partnered with CEPI.https://www.biopharmadive.com/news/gilead-gsk-coronavirus-antiviral-clinical-trial/571583/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
With $420M in Q4 revenues,
$VRTX's cystic fibrosis drug Trikafta performed 5x better than expected — and capped off an 8-year growth story for the biotech's CEO.https://www.biopharmadive.com/news/vertex-trikafta-launch-cystic-fibrosis-leiden/571452/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Too few women and people of color are in executive positions or on the boards of biotech companies, according to a new report from BIO.https://www.biopharmadive.com/news/biotech-diversity-leadership-women-bio-report/571495/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Competition is heating up for copycats to
$RHHBY's top-selling cancer drugs, as the U.S. biosimilar market shows some modest signs of shifting$AMGN$PFE$BIIBhttps://www.biopharmadive.com/news/amgen-pfizer-biosimilar-growth-herceptin-avastin/571502/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioPharma Dive proslijedio/la je Tweet
If you haven't yet, check out
@BioPharmaDive's latest deep dive. After years being all-in on brain drugs, big pharma pulled back. Is a return on the horizon? And, if so, what effects might it have on drug research?#biotech#pharma#neurosciencehttps://www.biopharmadive.com/news/pharma-neuroscience-retreat-return-brain-drugs/570250/ …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Spinraza rivals and Tecfidera patent challenges were in the spotlight as
$BIIB provided few details about its planned filing for aducanumab.https://www.biopharmadive.com/news/biogen-earnings-aducanumab-tecfidera-spinraza/571413/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$LLY's top scientist, however, set low expectations the drug will show a clear benefit.https://www.biopharmadive.com/news/lilly-preventive-alzheimers-dian-tu-study-within-weeks/571411/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Biotech execs see a new era of neuroscience advances ahead. But it's hard to pinpoint what would cause pharma to dive back in — and what ripples that would create.https://www.biopharmadive.com/news/pharma-neuroscience-retreat-return-brain-drugs/570250/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The Third Rock-backed company put an acting executive in place as it repositions for development in gene therapy and regenerative medicine.https://www.biopharmadive.com/news/decibel-ceo-steps-down-job-cuts-restructuring/571332/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Another 100 infants received
$NVS' Zolgensma in the fourth quarter, supported by broad insurance coverage and more newborn screening.https://www.biopharmadive.com/news/novartis-zolgensma-gene-therapy-sales-momentum/571302/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.